BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-450-6804500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$35,000.00
Profitability
Miscellaneous
Employees10
Next Earnings Date8/14/2019 (Estimated)
OptionableNot Optionable
BELLUS Health (TSE:BLU) Frequently Asked Questions
What is BELLUS Health's stock symbol?
BELLUS Health trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BLU."
How were BELLUS Health's earnings last quarter?
BELLUS Health Inc (TSE:BLU) announced its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.01. The company earned $0.01 million during the quarter, compared to analyst estimates of $0.01 million. View BELLUS Health's Earnings History.
When is BELLUS Health's next earnings date?
What is the consensus analysts' recommendation for BELLUS Health?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BELLUS Health.
Has BELLUS Health been receiving favorable news coverage?
Media coverage about BLU stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. BELLUS Health earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for BELLUS Health.
Who are some of BELLUS Health's key competitors?
Some companies that are related to BELLUS Health include Concordia International (CXR), Polynovo (PNV), Mesoblast (MSB), Resverlogix (RVX), Theratechnologies (TH), Oxford BioMedica (OXB), Starpharma (SPL), Neptune Wellness Solutions (NEPT), Biotest (BIO), Kodiak Sciences (KOD), Emerald Health Therapeutics (EMH), Senesco Technologies (ELOX), Monash IVF Group (MVF), Rafael (RFL) and Paradigm Biopharmaceuticals (PAR).
What other stocks do shareholders of BELLUS Health own?
Who are BELLUS Health's key executives?
BELLUS Health's management team includes the folowing people:
- Mr. Roberto Bellini, Pres, CEO & Director (Age 39)
- Mr. François Desjardins C.A., CPA, CPA, CA, VP of Fin. (Age 56)
- Dr. Denis Garceau, Sr. VP of Drug Devel. (Age 62)
- Mr. Tony Matzouranis, VP of Bus. Devel. (Age 46)
- Mr. Sébastien Roy, Corp. Sec. (Age 43)
How do I buy shares of BELLUS Health?
Shares of BLU and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is BELLUS Health's stock price today?
One share of BLU stock can currently be purchased for approximately C$1.92.
How big of a company is BELLUS Health?
What is BELLUS Health's official website?
How can I contact BELLUS Health?
BELLUS Health's mailing address is 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada. The company can be reached via phone at +1-450-6804500.
MarketBeat Community Rating for BELLUS Health (TSE BLU)
MarketBeat's community ratings are surveys of what our community members think about BELLUS Health and other stocks. Vote "Outperform" if you believe BLU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLU will underperform the S&P 500 over the long term. You may vote once every thirty days.
